NCT05952778 is a clinical trial in Skin Flaps, sponsored by M.D. Anderson Cancer Center.

Who is sponsoring NCT05952778?

NCT05952778 is sponsored by M.D. Anderson Cancer Center.

What condition does NCT05952778 study?

NCT05952778 studies Skin Flaps, Lung Cancer.

Is NCT05952778 still recruiting?

NCT05952778 is currently active, enrolled. Last updated 9 April 2026.

Last reviewed 2026-04-09 · How we verify

NCT05952778

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Reminder Messages for Lung Cancer Screening

Active, enrolled Last updated 9 April 2026

What this trial tests

trial in Skin Flaps in 133 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

20 June 2023

Primary endpoint
31 December 2029

31 December 2029

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	133
Start date	20 June 2023
Primary completion	31 December 2029
Estimated completion	31 December 2029
Sites	1 location across United States

Conditions studied

Skin Flaps — all drugs for Skin Flaps →
Lung Cancer — all drugs for Lung Cancer →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

Adults 40 to 80, any sex, with Skin Flaps or Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To test lung cancer screening reminder messages to help adults who 1) 50 to 80 years of age, 2) smoke or have smoked, and 3) do not have history of lung cancer by self-report.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05952778 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 9 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05952778.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing